You are here

TRACON Pharmaceuticals to Present at 2018 Wells Fargo Healthcare Conference

SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate update at the 2018 Wells Fargo Healthcare Conference at 9:05 pm EDT on Wednesday, September 5, 2018, at the Westin Waterfront in Boston, MA.

To access a live webcast of the presentation, please visit the “Events & Presentations” section within the “Investors” section of the TRACON Pharmaceuticals website at  A replay of the webcast will be available on the website for 60 days following the event.


TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at

Company Contact:
Mark Wiggins
Chief Business Officer
(858) 251-3492

Investor Contact:
Andrew McDonald
LifeSci Advisors LLC

Wednesday, August 29, 2018 - 16:05